Regeneron Pharmaceuticals Inc.
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| oncology | ×1.50 | 3 |
By stage at signing
Not enough phase-specific data (need ≥3 deals per phase).
Strategy profile
Based on 15 disclosed transactions, Regeneron Pharmaceuticals Inc. concentrates its licensing activity in Oncology, Other, and Cardiovascular. Regeneron Pharmaceuticals Inc. pays a 1.50x premium over market median, with the strongest premiums in Oncology (1.50x). Their most common deal structure is Collaboration, with an average disclosed value of $1.4B. Most recent activity: 2026.
Premium by therapeutic area
How Regeneron Pharmaceuticals Inc. pays relative to peer medians in each TA
Pipeline coverage & gaps
Regeneron Pharmaceuticals Inc. has disclosed activity in 1 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| CollaborationPrimary | 12 | $84M | $1.5B |
| License | 2 | $50M | $1.1B |
| Co Development | 1 | $150M | $275M |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | — | Parabilis Medicines | — | discovery | $50M | $2.3B |
| 2026 | Conditionally activated antibody / T-cell engager programs (up to 8 targets) | CytomX Therapeutics | oncology (multiple immuno-oncology targets) | discovery | — | $2.0B |
| 2026 | Multiple targets (collaboration expansion) | CytomX Therapeutics | cancer | unknown | — | $2.0B |
| 2026 | Conditionally activated BTK inhibitor program | CytomX Therapeutics | oncology / immuno-oncology | preclinical | $37M | $2.0B |
| 2026 | Antibody-Helicon™ Conjugates (AHCs) | Parabilis Medicines | — | discovery | $50M | $2.3B |
| 2026 | Parabilis ADC platform | Parabilis | oncology | discovery | $125M | $2.3B |
| 2026 | Telix Pharmaceuticals radiopharma pact | Telix Pharmaceuticals Limited | solid tumors including lung cancer | discovery | $40M | $2.1B |
| 2025 | TSRA-196 (AATD) | Tessera Therapeutics | alpha-1 antitrypsin deficiency | preclinical | $150M | $275M |
| 2025 | lentiviral-vector CAR-T program | JW Therapeutics | cell immunotherapy oncology | unknown | — | $50M |
| 2025 | — | ModeX Therapeutics | other | discovery | $7M | $1.0B |
| 2025 | HS-20094 (olatorepatide) | Hansoh Pharmaceutical Group | obesity | unknown | $80M | $2.0B |
| 2025 | B7-H4-201 | Hengrui Medicine | AML | preclinical | $19M | $272M |
| 2025 | Truveta Genome Project | Truveta | genomics and real-world evidence platform | discovery | $120M | $120M |
| 2024 | atherosclerosis | Intellia Therapeutics | atherosclerosis | phase_1 | $75M | $700M |
| 2024 | dyslipidemia | Alnylam Pharmaceuticals | dyslipidemia | phase_2 | $250M | $1.4B |
How this is computed
For each Regeneron Pharmaceuticals Inc. deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 6 disclosed deal premiums vs. peer medians. Raw premium 2.062, clamped to [0.7, 1.5].